COMMUNIQUÉS West-GlobeNewswire

Vericel Reports Second Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance

06/08/2019 - 13:00

Record Second Quarter Product Revenues of $26.2 Million Represent a 38% Increase Over Second Quarter 2018 Full Year 2019 Revenue Guidance Raised to $112 to $116 Million Conference Call Today at 8:00am Eastern Time [...]

Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement

06/08/2019 - 13:00

• Combined company capitalized with approximately $65M to develop novel immunotherapies • Sophisticated computational platform enables new class of de novo protein therapeutics • Lead program, NL-201, is a potent IL-2/ [...]

Evelo Biosciences Announces Positive Interim Phase 1b Clinical Data and Provides Second Quarter 2019 Financial Results

06/08/2019 - 13:00

-EDP1815 and EDP1066 were Well Tolerated with No Overall Difference Reported from Placebo- -Clinical Response Observed Consistent with Reductions in Cellular Histological and Blood Immune Cell Biomarkers in Psoriasis [...]

Emerald Health Therapeutics Outlines Production and Processing Advancements

06/08/2019 - 13:00

VICTORIA, British Columbia, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today provided updates on its various cultivation and processing initiatives. “With [...]

Foundation Fighting Blindness selects Guardion’s VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-Center Clinical Trial

06/08/2019 - 13:00

The CSV-1000 Diagnostic Instrument is Considered the Standard of Care for the Measurement of Contrast Sensitivity San Diego, CA, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “ [...]

Todos Medical Appoints Dr. Jorge Leon as Medical Advisor

06/08/2019 - 13:00

Dr. Leon previously played a key role in establishing and leading Quest Diagnostics’ Molecular Diagnostics laboratories. REHOVOT, Israel, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical- [...]

Rockwell Medical, Inc. Announces Acceptance by FDA of New Drug Application for I.V. TRIFERIC®

06/08/2019 - 12:50

–FDA establishes PDUFA date of March 28, 2020 for I.V. Triferic – WIXOM, Mich., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company [...]

TCR2 Therapeutics Deepens Manufacturing and Immuno-Oncology Expertise with Key Hires

06/08/2019 - 12:45

Expansion of leadership team to support clinical trials with an emphasis on manufacturing, IND enablement and development of next generation of TRuC-T cells CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- TCR 2 [...]

Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights

06/08/2019 - 12:45

DEVON, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric [...]

AnaptysBio to Present at the Wedbush PacGrow 2019 Healthcare Conference

06/08/2019 - 12:30

SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, [...]

Syneos Health Reports Second Quarter 2019 Results

06/08/2019 - 12:14

Highlights GAAP revenue of $1,166.8 million for the three months ended June 30, 2019, representing growth of 8.8% compared to the same period in 2018. Adjusted revenue of $1,168.4 million for the three months ended June [...]

Digirad Corporation Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2019

06/08/2019 - 11:55

Performed ahead of expectations for revenue, highlighted by Diagnostic Imaging growth of 11% year over year Made significant progress towards “HoldCo” transformation by completing initial filing of registration [...]

Transactions in relation to share buyback program

06/08/2019 - 11:23

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 1, 2019, in accordance with article 5 of Regulation (EU) no. 596/2014 of April 16, 2014 on [...]

Release date of six-month interim report (Q2) 2019 for ALK and audio cast

06/08/2019 - 10:00

On Tuesday, 13 August 2019, ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) releases its six-month interim report (Q2) 2019. ALK will host a meeting for analysts and institutional investors that day at 13.30 p.m. (CEST) at [...]

AroCell signs a new distributor agreement in the USA and Canada

06/08/2019 - 08:15

AroCell AB (publ) announced today that it has signed a distribution agreement with Diapharma Group of West Chester Ohio for the promotion and distribution of the AroCell TK 210™ ELISA in the United States and Canada. [...]

Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019

06/08/2019 - 08:00

Initiated Phase 2b study with nebulized ensifentrine as add-on to long-acting bronchodilator Initiated first Phase 2 study with metered-dose inhaler formulation Post-period end reported positive Phase 2 data with dry [...]

Acarix AB (publ) publishes Interim Report, January – June 2019

06/08/2019 - 08:00

Acarix AB (publ) publishes Interim Report, January – June 2019 Malmö, August 6, 2019 CADScor®System Included in UK guidance for ruling out Coronary Artery Disease ”With CADScor®System we have a fantastic opportunity to [...]

ReWalk Robotics to Report Second Quarter 2019 Financial Results on August 8, 2019

06/08/2019 - 07:42

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Aug. 06, 2019 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its second quarter 2019 [...]

Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure infections (ABSSSI)

06/08/2019 - 07:15

Ceftobiprole met primary and secondary efficacy endpoints in the treatment of ABSSSI Ceftobiprole was well tolerated Basel, Switzerland, August 06, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today positive [...]